These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 22890091

  • 1. Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
    Chen Y, Yang H, Lu G, Wu X, Huang W, Wu Y, Lv X, Wu G, Zhang G, Li Q, Sun Y.
    Chemotherapy; 2012; 58(3):249-56. PubMed ID: 22890091
    [Abstract] [Full Text] [Related]

  • 2. Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections.
    Carmignani G, De Rose AF, Olivieri L, Salvatori E, Rosignoli MT, Dionisio P.
    Urol Int; 2005; 74(4):326-31. PubMed ID: 15897698
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y, Ozaki M, Matsuda M, Honmura T, Nishimura I, Yamaguchi R, Adachi T, Okawa Y, Nishino T.
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [Abstract] [Full Text] [Related]

  • 4. Prulifloxacin: a new antibacterial fluoroquinolone.
    Prats G, Rossi V, Salvatori E, Mirelis B.
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
    [Abstract] [Full Text] [Related]

  • 5. Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections.
    Rafailidis PI, Polyzos KA, Sgouros K, Falagas ME.
    Int J Antimicrob Agents; 2011 Apr; 37(4):283-90. PubMed ID: 21300527
    [Abstract] [Full Text] [Related]

  • 6. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial.
    Giannarini G, Mogorovich A, Valent F, Morelli G, De Maria M, Manassero F, Barbone F, Selli C.
    J Chemother; 2007 Jun; 19(3):304-8. PubMed ID: 17594926
    [Abstract] [Full Text] [Related]

  • 7. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis.
    Blasi F, Schaberg T, Centanni S, Del Vecchio A, Rosignoli MT, Dionisio P.
    Pulm Pharmacol Ther; 2013 Oct; 26(5):609-16. PubMed ID: 23538168
    [Abstract] [Full Text] [Related]

  • 8. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
    Noviello S, Ianniello F, Leone S, Esposito S.
    Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
    [Abstract] [Full Text] [Related]

  • 9. Randomized, double-blind, comparative study of levofloxacin and ofloxacin in the treatment of complicated urinary tract infections.
    Peng MY.
    J Microbiol Immunol Infect; 1999 Mar; 32(1):33-9. PubMed ID: 11561568
    [Abstract] [Full Text] [Related]

  • 10. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
    Peterson J, Kaul S, Khashab M, Fisher A, Kahn JB.
    Clin Ther; 2007 Oct; 29(10):2215-21. PubMed ID: 18042477
    [Abstract] [Full Text] [Related]

  • 11. Prulifloxacin: clinical studies of a broad-spectrum quinolone agent.
    Giannarini G, Tascini C, Selli C.
    Future Microbiol; 2009 Feb; 4(1):13-24. PubMed ID: 19207096
    [Abstract] [Full Text] [Related]

  • 12. Prulifloxacin.
    Keam SJ, Perry CM.
    Drugs; 2004 Feb; 64(19):2221-34; discussion 2235-6. PubMed ID: 15456336
    [Abstract] [Full Text] [Related]

  • 13. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
    Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ, Moran CT, Levofloxacin Bacterial Conjunctivitis Active Control Study Group.
    Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
    Gualco L, Schito AM, Schito GC, Marchese A.
    Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
    [Abstract] [Full Text] [Related]

  • 15. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
    Roveta S, Schito AM, Marchese A, Schito GC.
    Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
    [Abstract] [Full Text] [Related]

  • 16. Prulifloxacin vs Levofloxacin for Exacerbation of COPD after Failure of Other Antibiotics.
    Giusti M, Blasi F, Iori I, Mazzone A, Sgambato F, Politi C, Colagrande P, Casali A, Valerio A, Gussoni G, Bonizzoni E, Campanini M.
    COPD; 2016 Oct; 13(5):555-60. PubMed ID: 27027547
    [Abstract] [Full Text] [Related]

  • 17. Cefdinir versus levofloxacin in patients with acute rhinosinusitis of presumed bacterial etiology: a multicenter, randomized, double-blind study.
    Henry DC, Kapral D, Busman TA, Paris MM.
    Clin Ther; 2004 Dec; 26(12):2026-33. PubMed ID: 15823766
    [Abstract] [Full Text] [Related]

  • 18. Role of prulifloxacin in the treatment of acute rhinosinusitis.
    Passali D, Crisanti A, Bellussi LM.
    Infez Med; 2015 Dec; 23(4):301-6. PubMed ID: 26700078
    [Abstract] [Full Text] [Related]

  • 19. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH, Community-Acquired Pneumonia Recovery in the Elderly Study Group.
    Clin Infect Dis; 2006 Jan 01; 42(1):73-81. PubMed ID: 16323095
    [Abstract] [Full Text] [Related]

  • 20. Clinical and microbiological efficacy of prulifloxacin for the treatment of chronic bacterial prostatitis due to Chlamydia trachomatis infection: results from a prospective, randomized and open-label study.
    Cai T, Mazzoli S, Addonisio P, Boddi V, Geppetti P, Bartoletti R.
    Methods Find Exp Clin Pharmacol; 2010 Jan 01; 32(1):39-45. PubMed ID: 20383345
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.